U.S. markets closed

Johnson & Johnson (JNJ)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
160.39+0.47 (+0.29%)
At close: 4:00PM EDT

160.65 +0.26 (0.16%)
After hours: 7:59PM EDT

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Triple Moving Average Crossover

Triple Moving Average Crossover

Previous Close159.92
Open160.72
Bid160.30 x 800
Ask160.90 x 800
Day's Range160.23 - 162.39
52 Week Range133.65 - 173.65
Volume7,333,828
Avg. Volume8,200,523
Market Cap422.26B
Beta (5Y Monthly)0.72
PE Ratio (TTM)29.11
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield4.04 (2.53%)
Ex-Dividend DateFeb 22, 2021
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-25% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Johnson & Johnson Announces Advance Purchase Agreement with the African Vaccine Acquisition Task Team for the Company's COVID-19 Vaccine Candidate
    PR Newswire

    Johnson & Johnson Announces Advance Purchase Agreement with the African Vaccine Acquisition Task Team for the Company's COVID-19 Vaccine Candidate

    Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ) (the Company), has entered into an agreement with the African Vaccine Acquisition Task Team (AVATT) to make available up to 220 million doses of its single-shot COVID-19 vaccine candidate to African Union's 55 member states with delivery beginning in the third quarter of 2021. AVATT also has the potential to order an additional 180 million doses, for a combined total of up to 400 million doses through 2022. The availability of the vaccine candidate is subject to its successful approval or authorization by the national regulatory authorities of AU member states.

  • Johnson & Johnson Announces Advance Purchase Agreement with the African Vaccine Acquisition Trust for the Company's COVID-19 Vaccine Candidate
    PR Newswire

    Johnson & Johnson Announces Advance Purchase Agreement with the African Vaccine Acquisition Trust for the Company's COVID-19 Vaccine Candidate

    Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ) (the Company), has entered into an agreement with the African Vaccine Acquisition Trust (AVAT) to make available up to 220 million doses of its single-shot COVID-19 vaccine candidate to African Union's 55 member states with delivery beginning in the third quarter of 2021. AVAT also has the potential to order an additional 180 million doses, for a combined total of up to 400 million doses through 2022. The availability of the vaccine candidate is subject to its successful approval or authorization by the national regulatory authorities of AU member states.

  • Johnson & Johnson Single-Shot COVID-19 Vaccine Granted Emergency Use Listing by the World Health Organization
    PR Newswire

    Johnson & Johnson Single-Shot COVID-19 Vaccine Granted Emergency Use Listing by the World Health Organization

    Johnson & Johnson (NYSE: JNJ) (the Company) today announced that the World Health Organization (WHO) has issued Emergency Use Listing (EUL) for its single-shot COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), to prevent COVID-19 in individuals 18 years of age and older.